

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2017

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A-; B7, B51; Cw6, Cw7; DR4, DR8; DQ4, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	9	10	9	10	21	21	19	20	20	20	20	20	20			
Positive	1	0	5	3	1	0	6	1	17	9	20	15				
Negative	8	10	4	7	20	21	13	19	3	11	0	5				
NT/Equivocal	1	0	1	0	0	0	2	1	2	2	2	2				
% Positive	11.1%	0.0%	55.6%	30.0%	4.8%	0.0%	31.6%	5.0%	85.0%	45.0%	100.0%	75.0%				
% Negative	88.9%	100.0%	44.4%	70.0%	95.2%	100.0%	68.4%	95.0%	15.0%	55.0%	0.0%	25.0%				
<b>Consensus</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Positive</b>	<b>Not Assessed</b>	<b>Positive</b>	<b>Positive</b>				
HLA Antibody Specificity (Defined By CDC)	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Without DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Equivocal	Negative	Positive	Positive	Negative	Negative	Positive	Equivocal	Positive	Negative	Positive	Positive	
11	YES	YES	YES	Negative	Negative	Equivocal	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cell crossmatch uninterpretable due to poor cell viability
14		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
20	YES		YES	Negative	Negative	Positive	Negative					Negative	Positive	Positive	Negative	Low cell viability in B cell prep. We would not report these results in a clinical situation
23		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
24		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
25		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
28		YES	YES					Negative	Negative	Negative	Negative	Weak Positive	Negative	Positive	Positive	
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
35	YES	YES		Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative					
38	YES	YES	YES	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative	
39		YES	YES					Positive	Negative	Positive	Negative	NT	NT	NT	NT	Too few B cells to report
41		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
42	YES		YES	Negative	Negative	Negative	Negative					Positive	Positive	Positive	Positive	Insufficient sample to repeat for B cell crossmatch, therefore assigned Equivocal
45		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
51		YES	YES					Negative	Negative	Positive	Negative	Positive	Positive	Positive	Positive	Very poor cells. Would want to repeat with fresh blood if clinical
54		YES	YES					Negative	Negative	Equivocal	Negative	Positive	Positive	Positive	Positive	
58		YES	YES					Negative	Negative	Equivocal	Negative	Positive	Positive	Positive	Positive	
117	YES			Negative	Negative	Negative	Negative									
136	YES							Negative	Negative	Negative	Negative					
149	YES			Negative	Negative	Negative	Negative									
205	YES		YES	Positive	Negative	Positive	Negative					Positive	Negative	Positive	Negative	
212		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
311		YES	YES					Negative	Negative	Positive	Negative	Positive	Positive	Positive	Positive	
315		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2017

DESPATCHED ON 28TH MARCH 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	-	-	4	2	-	-	6	-	2	-	6	4	95	95	95
11	-	-	-	-	-	-	-	-	8	6	8	8	90	90	90
12	1	1	1	1	1	1	1	1	NT	NT	NT	NT	95	95	50
14					0	0	0	0	8	6	8	8		90	80
20	1	1	4	1					1	1	9	1	90		60
23					1	1	1	1	8	2	8	8		90	30
24					20	10	20	10	90	80	100	90		90	90
25					1	1	1	1	6	1	8	6		99	99
28					1	1	1	1	4	1	8	8			
34					1	1	1	1	6	1	8	8		99	99
35	1	1	2	2	1	1	2	1					90	50	
38	1	1	4	2	1	1	4	2	1	1	8	1	95	90	85
39					2	-	2	-	NT	NT	NT	NT		90	
41					5	5	8	5	30	5	100	40		95	95
42	<10	<10	~10	<10					20-40	<10	>80	>80	95		95
45					1	1	1	1	8	6	6	6		99	99
51					0	0	1-2	0	8	8	8	8		75	70
54					10	20	40	10	100	90	100	90		99	99
58					5	5	10	5	70	40	100	80		95	95
117	1	1	1	1									80		
136					-	-	-	-						98	
149	-	-	-	-									77		
205	++++	-	+	-					++++	-	++++	-	80		80
212					-	-	-	-	-	-	-	-		95	95
311					1	1	2	1	8	6	8	8		90	90
315					1	1	1	1	8	1	8	1		80	80

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2017

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A-; B7, B51; Cw6, Cw7; DR4, DR8; DQ4, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
				7	8	7	8	17	17	16	16	17	17	18	17	
				1	0	4	2	0	0	5	1	14	4	18	11	
				6	8	3	6	17	17	11	15	3	13	0	6	
				2	1	2	1	2	2	3	3	4	4	3	4	
				14.3%	0.0%	57.1%	25.0%	0.0%	0.0%	31.3%	6.3%	82.4%	23.5%	100.0%	64.7%	
				85.7%	100.0%	42.9%	75.0%	100.0%	100.0%	68.8%	93.8%	17.6%	76.5%	0.0%	35.3%	
<b>Consensus</b>				<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Positive</b>	<b>Negative</b>	<b>Positive</b>	<b>Not Assessed</b>	
HLA Antibody Specificity (Defined By CDC)				A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	<b>Equivocal</b>	Negative	Positive	<b>Positive</b>	Negative	Negative	Positive	<b>Equivocal</b>	Positive	Negative	Positive	Positive	B cell crossmatch uninterpretable due to poor cell viability
11	YES	YES	YES	Negative	Negative	<b>Equivocal</b>	Negative	Negative	Negative	Negative	Negative	Positive	<b>Positive</b>	Positive	Positive	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	
14		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	No lymphocytes, not enough to carry out CDC
15		YES	YES					<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	
20	YES		YES	Negative	Negative	Positive	Negative					<b>Negative</b>	Negative	Positive	Negative	Samples failed DTT testing
24		YES	YES					Negative	Negative	Negative	Negative	Positive	<b>Positive</b>	Positive	Positive	
25		YES	YES					Negative	Negative	Negative	Negative	<b>Equivocal</b>	Negative	Positive	<b>Equivocal</b>	
28		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
35	YES	YES	YES	<b>Equivocal</b>	<b>Equivocal</b>	<b>Equivocal</b>	<b>Equivocal</b>	<b>Equivocal</b>	<b>Equivocal</b>	<b>Equivocal</b>	<b>Equivocal</b>					
38	YES	YES	YES	Negative	Negative	Positive	<b>Positive</b>	Negative	Negative	Positive	<b>Positive</b>	<b>Negative</b>	Negative	Positive	Negative	
39		YES	YES					Negative	Negative	Positive	Negative	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	Too few B cells to report
41		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
42	YES		YES	Negative	Negative	Negative	Negative					Positive	<b>Equivocal</b>	Positive	Positive	Insufficient sample to repeat for B cell crossmatch, therefore assigned Equivocal
45		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
51		YES	YES					Negative	Negative	Positive	Negative	Positive	<b>Positive</b>	Positive	Positive	Very poor cells. Would want to repeat with fresh blood if clinical
58		YES	YES					Negative	Negative	<b>Equivocal</b>	Negative	Positive	<b>Positive</b>	Positive	Positive	
149	YES		YES	Negative	Negative	Negative	Negative					Positive	Negative	Positive	Negative	
205	YES		YES	<b>Positive</b>	Negative	Positive	Negative					<b>Negative</b>	Negative	Positive	Negative	
212		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
311		YES	YES					Negative	Negative	Positive	Negative	Positive	Negative	Positive	Positive	
315		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2017

DESPATCHED ON 28TH MARCH 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	-	-	4	2	-	-	6	-	2	-	6	4	95	95	95
11	-	-	-	-	-	-	-	-	8	6	8	8	90	90	90
12	1	1	1	1	1	1	1	1	NT	NT	NT	NT	95	95	50
14					0	0	0	0	4	0	8	8		90	80
15					NT	NT	NT	NT	NT	NT	NT	NT			
20	1	1	2	1					1	1	9	1	90		60
24					10	20	20	20	80	60	100	100		90	90
25					1	1	1	1	-	1	8	-		99	99
28					1	1	1	1	6-8	1	8	8			
34					1	1	1	1	4	1	8	6		99	99
35	NT	NT	NT	NT	NT	NT	NT	NT							
38	1	1	4	2	1	1	2	2	1	1	8	1	95	90	85
39					-	-	2	-	NT	NT	NT	NT		90	
41					5	5	12	8	60	5	100	75		95	95
42	<10	<10	~10	<10					20-40	<10	>80	>80	95		95
45					1	1	1	1	8	1	6	1		99	99
51					0	0	1-2	0	8	4-6	8	8		75	70
58					5	5	10	5	80	80	100	99		95	95
149	-	-	-	-									77		
205	++++	-	+	-					++++	-	++++	-	80		80
212					-	-	-	-	-	-	-	-		95	95
311					1	1	2	1	8	1	8	8		90	90
315					1	1	1	1	8	1	8	1		80	80